From the Research
Sodabicard is more likely to cause hypokalemia, or low potassium levels in the blood, as evidenced by the most recent and highest quality study available 1. The mechanism by which Sodabicard leads to hypokalemia involves the shift of potassium from the extracellular fluid into cells as the blood becomes more alkaline, reducing the concentration of potassium in the bloodstream. Key points to consider include:
- The prevalence of hypokalemia in patients taking diuretics, which can be as high as 56% according to previous studies 1
- The importance of monitoring potassium levels in patients receiving Sodabicard therapy, especially those at risk for electrolyte imbalances or taking medications that affect potassium levels such as diuretics
- The dose-dependent nature of the hypokalemic effect, which is more pronounced with rapid administration or high doses
- The potential for Sodabicard to cause cardiac arrhythmias or other complications of hypokalemia, particularly in emergency situations where it is used to treat severe acidosis Other studies have also highlighted the risk of hypokalemia associated with diuretic use, including a study from 1995 that found a prevalence of hypokalemia of 21.1% in patients taking potassium-losing diuretics 2. Additionally, a 2018 study noted that the optimal potassium level in patients with chronic kidney disease is unknown, but that both hypokalemia and hyperkalemia can have adverse outcomes 3. However, the most recent and highest quality evidence suggests that Sodabicard is more likely to cause hypokalemia, and therefore patients receiving Sodabicard therapy should have their potassium levels closely monitored to prevent complications 1.